08:25 AM EST, 11/18/2024 (MT Newswires) -- Shares of Regenxbio ( RGNX ) were surging premarket Monday after the biotechnology company reported new, positive data from the phase I/II portion of a study evaluating RGX-202 gene therapy for Duchenne muscular dystrophy.

The company also said the gene therapy has advanced to a pivotal stage with a first patient dosed. RGX-202 will now be evaluated in the pivotal trial in about 30 patients aged 1 and older, according to Regenxbio ( RGNX ).

Regenxbio ( RGNX ) also said it is "quickly advancing" the gene therapy toward a biologics license application filing in 2026.

Price: 9.19, Change: +0.40, Percent Change: +4.60